Return to search results.
Complete title: Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution after Myeloablative Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected with HIV
|Research Study Number||2212.00|
|Principal Investigator||Ann Woolfrey, MD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Genders Eligible for Study: Both
- Age < 66 years for autologous recipients; ages < 76 for allogeneic recipients
- HIV positive
- Treatment with highly active antiretroviral therapy (HAART) for at least 1 month
- Viral load has decreased by >= 1.5 logs or viral load < 5000 copies/ml plasma on HAART therapy
- Hematologic malignancy associated with a poor prognosis or other diagnosis for which hematopoietic cell therapy (allogeneic or autologous, including gene therapy) is indicated
- Approval for allogenic regimen given at Patient Care Conference
- DONOR: Autologous or allogeneic gene modified cells allowed
Other eligibility criteria may apply.
Exclusions (conditions that would prevent participation in this study)
- Inability to provide informed consent
- DONOR: Allogeneic donors must not have HIV infection
Other exclusion criteria may apply.
Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Hematologic Malignancies; Immunodeficiency Syndromes
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.